The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).
Julie R. Brahmer
No relevant relationships to disclose
Leora Horn
Consultant or Advisory Role - OSI/Astellas (U)
Scott Antonia
No relevant relationships to disclose
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Leena Gandhi
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
Jon Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dan McDonald
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb (B)
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Scott N. Gettinger
No relevant relationships to disclose